CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
egfr
A collection of 27 issues
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models
Skip to content
The CRC Digest
◇ RESEARCH
Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models
A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The
Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC
Skip to content
The CRC Digest
◇ RESEARCH
Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC
Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops.
CRC Research Update — September 01, 2026
Today's colorectal cancer research highlights
Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
Pooled Analysis Identifies Predictive Biomarkers for Cetuximab Rechallenge in Metastatic Colorectal Cancer
Pooled analysis of 180 patients from the CAVE and CAVE-2 studies investigates clinical variables that predict response to cetuximab rechallenge (with or without avelumab) in patients with circulating tumor DNA RAS/
CRC Research Update — August 28, 2026
Today's colorectal cancer research highlights
Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC
A phase Ib/II study (NCT05176665) of EMB-01, a novel EGFR × c-MET bispecific antibody, enrolled 52 patients with heavily pretreated metastatic colorectal cancer. EMB-01 was administered at 1600 mg intravenously weekly, with primary
CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC
Skip to content
The CRC Digest
▸ TREATMENT
RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC
A case report describes a patient with RAF1 S257L-mutated, anti-EGFR-refractory metastatic CRC who achieved radiographic response and performance status improvement with avutometinib (RAF/MEK clamp inhibitor) plus cetuximab. (Oncologist)
This content